- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.12.25 | Acquisitive Sanofi keeps deals coming, laying out $2.2B for hepatitis vaccine maker Dynavax | ||
| 26.12.25 | Omeros scores its first-ever FDA nod as stem cell transplant drug Yartemlea approved | ||
| 23.12.25 | Baltimore jury orders J&J to pay $1.5B in largest-ever award to a talc plaintiff | ||
| 23.12.25 | Pfizer confirms patient death in Hympavzi hemophilia extension study | ||
| 23.12.25 | Neurocrine's Ingrezza fails phase 3 trial for cerebral palsy | ||
| 23.12.25 | What a year: Here are the stories that captivated our audience in 2025 | ||
| 23.12.25 | AstraZeneca, betting on radiopharmaceuticals, extends Niowave isotope supply deal by 10 years | ||
| 22.12.25 | FDA comes bearing gifts early for Cytokinetics and blockbuster-to-be Myqorzo | ||
| 22.12.25 | BI's Jascayd quickly expands lung disease reach with new FDA nod | ||
| 22.12.25 | Turning up the volume on colorectal cancer awareness drives diagnosis in Nigeria | ||
| 22.12.25 | With FDA approval, Roche's blood cancer bispecific Lunsumio goes subcutaneous | ||
| 22.12.25 | ALS med Radicava to change hands as Shionogi inks $2.5B buyout | ||
| 22.12.25 | Incog to spend $200M on capacity boost at Indiana sterile injectables plant | ||
| 22.12.25 | Samsung Biologics pays GSK $280M to secure first US manufacturing site | ||
| 19.12.25 | 9 pharma giants reach US drug price deals with Trump administration | ||
| 19.12.25 | AstraZeneca to pull bleeding reversal agent Andexxa after FDA flags risk imbalance | ||
| 19.12.25 | FDA outlined concerns with Elevidys manufacturing at Catalent site, Form 483 shows | ||
| 19.12.25 | BioMarin makes largest-ever transaction, paying $4.8B for fellow rare disease drugmaker Amicus | ||
| 19.12.25 | BMS' Cobenfy TV ad is latest target of FDA untitled letter spree | ||
| 19.12.25 | Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement | ||
| 19.12.25 | Cybin alters state to become Helus Pharma for Nasdaq trip | ||
| 19.12.25 | A year in review and what 2026 holds for biopharma and healthcare | ||
| 19.12.25 | 2026 forecast: Pharma clicks with patients as direct sales model shifts marketing strategies | ||
| 18.12.25 | Medtronic encourages people with Type 1 diabetes to 'Own It' in new MiniMed campaign | ||
| 18.12.25 | High-flying Insmed stumbles with rhinosinusitis trial failure for Brinsupri |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.